NCT03759782View on ClinicalTrials.gov

Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

PHASE3UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

September 30, 2022

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Ribavirin

Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.

DRUG

Tenofovir

Tenofovir as per standard of care

Trial Locations (2)

T2N4Z6

RECRUITING

Cumming School of Medicine, University of Calgary, Calgary

K1H8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER